Pharmacoeconomic Analysis of Using Aprepitant Plus Standard Antiemetic Therapy for Prevention of Nausea and Vomiting Associated With Highly and Moderately Emetogenic Cancer Chemotherapy in Russia

Value in Health- United Kingdom

doi 10.1016/j.jval.2013.08.521

Full Text

Abstract

Available in

Date

November 1, 2013

Authors

I. Krysanov

V. Krysanova

Publisher

Elsevier BV

Related search

Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.

Journal of Clinical Oncology

English

Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting

Cancer Research and Treatment

Cancer Research

Oncology

2020

English

Effects of Serum Sodium Concentrations on Nausea and Vomiting After Moderately Emetogenic Chemotherapy

Yakugaku Zasshi

Pharmacology

Pharmaceutical Science

2018

English

Incidence of Chemotherapy-Induced Nausea and Vomiting With Moderately Emetogenic Chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) Study

Supportive Care in Cancer

Oncology

2015

English

Efficacy of the Combination Use of Aprepitant and Palonosetron for Improving Nausea in Various Moderately Emetogenic Chemotherapy Regimens

BMC pharmacology & toxicology

Medicine

Pharmacology

2019

English

Olanzapine Combined With Standard Antiemetic Regimens for Prevention of Chemotherapy Therapy-Induced Nausea and Vomiting: A Single-Center Experience From South India

Asian Journal of Pharmaceutical and Clinical Research

Pharmacology

Pharmaceutical Science

2017

English

Antiemetics for Chemotherapy-Induced Nausea and Vomiting Occurring Despite Prophylactic Antiemetic Therapy

Journal of Palliative Medicine

English

Cost-Effectiveness of an Aprepitant Regimen for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer in the UK

Cancer Management and Research

Oncology

2013

English

A Randomized, Placebo-Controlled Pilot Trial of Aprepitant Combined With Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Cyclophosphamide-Based Conditioning Regimens Prior to Hematopoietic Stem Cell Transplant (HSCT)

Bone Marrow Transplantation

Transplantation

Hematology

2018

English

Amanote Research

Pharmacoeconomic Analysis of Using Aprepitant Plus Standard Antiemetic Therapy for Prevention of Nausea and Vomiting Associated With Highly and Moderately Emetogenic Cancer Chemotherapy in Russia

Value in Health- United Kingdom

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Efficacy of Triple Antiemetic Therapy (Palonosetron, Dexamethasone, Aprepitant) for Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Carboplatin-Based, Moderately Emetogenic Chemotherapy.

Ramosetron Versus Palonosetron in Combination With Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting

Effects of Serum Sodium Concentrations on Nausea and Vomiting After Moderately Emetogenic Chemotherapy

Incidence of Chemotherapy-Induced Nausea and Vomiting With Moderately Emetogenic Chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) Study

Efficacy of the Combination Use of Aprepitant and Palonosetron for Improving Nausea in Various Moderately Emetogenic Chemotherapy Regimens

Olanzapine Combined With Standard Antiemetic Regimens for Prevention of Chemotherapy Therapy-Induced Nausea and Vomiting: A Single-Center Experience From South India

Antiemetics for Chemotherapy-Induced Nausea and Vomiting Occurring Despite Prophylactic Antiemetic Therapy

Cost-Effectiveness of an Aprepitant Regimen for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer in the UK

A Randomized, Placebo-Controlled Pilot Trial of Aprepitant Combined With Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Undergoing Cyclophosphamide-Based Conditioning Regimens Prior to Hematopoietic Stem Cell Transplant (HSCT)